Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arixtra for DVT Prophylaxis in Gynecologic Oncology Surgery
NCT00539942Phase 3Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2007
- Primary completion
- Jun 2010
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fondaparinux in deep vein thrombosis (DVT) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Comparison of Deep Venous Thromboembolism (DVT) Using Intermittent Compression Devices With and Without Arixtra at 21 days. Started Apr 2007; status: terminated.
02
Drugs
fondaparinux
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NCT00539942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00539942.